Corpus overview


MeSH Disease

Human Phenotype


    displaying 1 - 2 records in total 2
    records per page

    COVID-19 Myocardial Pathology Evaluated Through scrEening Cardiac Magnetic Resonance (COMPETE CMR)

    Authors: Daniel Eugene Clark; Amar Parikh; Jeffrey M Dendy; Alex B Diamond; Kristen George-Durrett; Frank A Fish; Warne Fitch; Sean G Hughes; Jonathan H Soslow; Nan Huo; Justin Stebbing; Davy Cheng

    doi:10.1101/2020.08.31.20185140 Date: 2020-09-02 Source: medRxiv

    Background Myocarditis HP Myocarditis MESHD is a leading cause of sudden cardiac death HP sudden cardiac death MESHD among competitive athletes and may occur without antecedent symptoms. COVID-19-associated myocarditis HP myocarditis MESHD has been well-described, but the prevalence SERO of myocardial inflammation MESHD and fibrosis MESHD in young athletes after COVID-19 infection MESHD is unknown. Objectives This study sought to evaluate the prevalence SERO and extent of cardiovascular involvement in collegiate athletes that had recently recovered from COVID-19. Methods We conducted a retrospective cohort analysis of collegiate varsity athletes with prior COVID-19 infection MESHD, all of whom underwent cardiac magnetic resonance (CMR) prior to resumption of competitive sports in August 2020. Results Twenty-two collegiate athletes with prior COVID-19 infection MESHD underwent CMR. The median time from SARS-CoV-2 infection MESHD to CMR was 52 days. The mean age TRANS was 20.2 years. Athletes represented 8 different varsity sports. This cohort was compared to 22 healthy controls and 22 tactical athlete controls. Most athletes experienced mild illness (N=17, 77%), while the remainder (23%) were asymptomatic TRANS. No athletes had abnormal troponin I, electrocardiograms, or LVEF < 50% on echocardiography. Late gadolinium enhancement was found in 9% of collegiate athletes MESHD and one athlete (5%) met formal criteria for myocarditis HP myocarditis MESHD. Conclusions Our study suggests that the prevalence SERO of myocardial inflammation MESHD or fibrosis MESHD after an asymptomatic TRANS or mild course of ambulatory COVID-19 among competitive athletes is modest (9%), but would be missed by ECG, Ti, and strain echocardiography. Future investigation is necessary to further phenotype cardiovascular manifestations of COVID-19 in order to better counsel athletes on return to sports participation.

    Pericarditis HP Pericarditis MESHD and myocarditis HP myocarditis MESHD long after SARS-CoV-2 infection MESHD: a cross-sectional descriptive study in health-care workers

    Authors: Rocio Eiros; Manuel Barreiro-Perez; Ana Martin-Garcia; Julia Almeida; Eduardo Villacorta; Alba Perez-Pons; Soraya Merchan; Alba Torres-Valle; Clara Sanchez-Pablo; David Gonzalez-Calle; Oihane Perez-Escurza; Ines Toranzo; Elena Diaz-Pelaez; Blanca Fuentes-Herrero; Laura Macias-Alvarez; Guillermo Oliva-Ariza; Quentin Lecrevisse; Rafael Fluxa; Jose L Bravo-Grandez; Alberto Orfao; Pedro L Sanchez

    doi:10.1101/2020.07.12.20151316 Date: 2020-07-14 Source: medRxiv

    Background: Cardiac sequelae of past SARS-CoV-2 infection MESHD are still poorly documented. We conducted a cross-sectional study in health-care workers to report evidence of pericarditis HP pericarditis MESHD and myocarditis HP myocarditis MESHD after SARS-CoV-2 infection MESHD. Methods We studied 139 health-care workers with confirmed past SARS-CoV-2 infection MESHD (103 diagnosed by RT-PCR and 36 by serology). Participants underwent clinical assessment, electrocardiography, laboratory tests including immune cell profiling and cardiac magnetic resonance (CMR) imaging. Pericarditis HP Pericarditis MESHD was diagnosed when classical criteria were present, and the diagnosis of myocarditis HP myocarditis MESHD was based on the updated CMR Lake-Louise-Criteria. Results: Median age TRANS was 52 years (IQR 41-57), 100 (72%) were women, and 23 (16%) were previously hospitalized for Covid-19 pneumonia HP pneumonia MESHD. At examination (10.4 [9.3-11.0] weeks after infection-like symptoms), all participants presented hemodynamic stability. Chest pain HP Chest pain MESHD, dyspnoea MESHD or palpitations HP were observed in 58 (42%) participants; electrocardiographic abnormalities in 69 (50%); NT-pro-BNP was elevated in 11 (8%); troponin in 1 (1%); and CMR abnormalities MESHD in 104 (75%). Isolated pericarditis HP pericarditis MESHD was diagnosed in 4 (3%) participants, myopericarditis in 15 (11%) and isolated myocarditis HP myocarditis MESHD in 36 (26%). Participants diagnosed by RT-PCR were more likely to still present symptoms than participants diagnosed by serology (73 [71%] vs 18 [50%]; p=0.027); nonetheless, the prevalence SERO of pericarditis HP pericarditis MESHD or myocarditis HP myocarditis MESHD was high in both groups (44 [43%] vs 11 [31%]; p=0.238). Most participants (101 [73%]) showed altered immune cell counts in blood SERO, particularly decreased eosinophil (37 [27%]; p<0.001) and increased CD4-CD8-/loT alpha beta-cell numbers (24 [17%]; p<0.001). Pericarditis HP Pericarditis MESHD was associated with elevated CD4-CD8-/loT alpha beta-cell numbers (p=0.011), while participants diagnosed with myopericarditis or myocarditis MESHD myocarditis HP had lower (p<0.05) plasmacytoid dendritic cell, NK-cell and plasma SERO cell counts and lower anti-SARS-CoV-2- IgG antibody SERO levels (p=0.027). Conclusions: Pericarditis HP Pericarditis MESHD and myocarditis HP myocarditis MESHD with clinical stability are frequent long after SARS-CoV-2 infection MESHD, even in presently asymptomatic TRANS subjects. These observations will probably apply to the general population infected and may indicate that cardiac sequelae might occur late in association with an altered (delayed) innate and adaptative immune response.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.



MeSH Disease
Human Phenotype

Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.